The synthesis and spectroscopic characterization of the rhodium(I) complex 1 incorporating a substituted thienopyrimidine ligand (tpc) was reported. The solid‐state structures of tpc and 1 were determined, for the first time, by single‐crystal X‐ray diffraction. The biological evaluation of the new compounds (tpc and 1) towards the PAF‐induced aggregation in both WRPs and human platelets (hPRPs) showed that complex 1 proved to be a very potent antiplatelet and antithrombotic agent, showing better efficiency than that of the free ligand.

If the food we eat is free of chemicals, then this means that we are going to start consuming less chemical and in the long run we are going to produce better and more nutritious food. The levels of cancer morbidity are going to reduce. There are also close links between chemical fertilisers and the value of organic food.

Antiplatelet therapies are discussed with a view to primary prevention of CVD by the clinical reduction of platelet reactivity and inflammation. Current antiplatelet therapies are effective in reducing cardiovascular risk but increase bleeding risk. Novel therapeutic antiplatelet approaches beyond current pharmacological modalities that do not increase the risk of bleeding require further investigation. There is potential for specifically designed nutraceuticals that may become safer alternatives to pharmacological antiplatelet agents for the primary prevention of CVD but there is serious concern over their efficacy and regulation, which requires considerably more research.